Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an investigational immunotherapy that is designed to bring together ...
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in ...
Darmstadt, Germany (ots/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to EUR20,000 - Shift.ms to Executive Produce a documentary to highlight stories and unique perspectives within the ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß ...
Darmstadt, Germany (ots/PRNewswire) - - Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo - Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine kinase inhibitor - First regulatory designation for tepotinib - SAKIGAKE ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years Merck, a leading science and technology company, today ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First treatment in relapsing-remitting multiple sclerosis (RRMS) to show sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Updated registration follows recent approval of Mavenclad in Europe and Canada Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Expanded Fertility Technology portfolio highlights Merck's commitment to improve fertility treatment outcomes for patients - U.S. commercial availability expected in first half of 2018 Merck, a leading science and technology company, today ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
Darmstadt, Germany (ots/PRNewswire) - - New pen is easy-to-learn and easy-to-use, supporting the one in six couples affected by infertility in the U.S.[1] - Insights of patients, nurses and doctors helped to evolve the product Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and ...
Darmstadt, Germany (ots/PRNewswire) - - First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe - Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years Merck, a leading science and technology company, today announced that the National Institute ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. based media. - Grant awarded across three research projects focused on prediction and defining characteristics of multiple sclerosis - Investment of EUR5 million in multiple sclerosis research funding as awards mark fifth year Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...
Darmstadt, Germany (ots/PRNewswire) - - Multiple sclerosis diagnosis has a profound impact on life choices including education, career, family planning and relationships - Almost 90% of women say multiple sclerosis played a role in their separation or divorce following diagnosis - Policy interventions could help address significant gender-specific challenges Merck, a ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on areas of high unmet need to help enhance ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK/U.S. based media - EUR1 million grant funded by Merck supports research with the potential to advance implementation of personalized treatment for solid tumors - Three winners selected from 100 scientifically diverse applicants worldwide Merck, a leading ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. or U.S. based media ESMO 2017 abstract # Erbitux®: 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib (c-Met kinase inhibitor): 701P - Data to showcase Merck's strong and diverse pipeline ranging from ...
Darmstadt, Germany (ots/PRNewswire) - - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe - MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Marketing authorization includes the 28 countries of the European Union (EU), with first ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Decision secures access to Erbitux® for new patients in England with oral cavity tumors - All patients currently receiving Erbitux® will have continued access Merck, a leading science and technology company, announced today that the ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T lymphocytes, with lymphocyte counts returning to normal range before the end of Year 2 - The lymphocyte data presented at EAN Congress are consistent with other clinical safety ...
Darmstadt, Germany (ots/PRNewswire) - - New data builds on company's longstanding commitment to MS Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 3rd Congress of the European Academy of Neurology (EAN), taking place from June 24-27, in Amsterdam, ...
Darmstadt, Germany (ots/PRNewswire) - - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical ...